Medytox announced that the project to develop 'MT122', a treatment for myasthenia gravis, was selected as the '3rd National New Drug Development Project in 2023' hosted by the Korea New Drug Development Foundation (KDDF).
The National New Drug Development Project is a government-wide R&D project that supports all stages of new drug development, including the discovery of candidate substances, non-clinical trials, and clinical trials, intending to strengthen the global competitiveness of the domestic biopharmaceutical industry. We will support research and development expenses to derive candidate substances for the next two years.
MT122 is an antibody treatment pipeline being developed to treat the rare autoimmune disease myasthenia gravis.' Unlike existing treatments, it has no immunosuppressive effect.
An official from Medytox said, "We are becoming a global biopharmaceutical company through the development of new pipelines, including 'MT107', a rare disease treatment currently in non-clinical testing, and 'MT117', 'MT124', and 'MT133', anticancer drugs, and 'MT921', a next-generation lipolysis injection."
The link to the Korean version of this article is as below.
▷메디톡스 "중증근무력증 치료제 ‘MT122’, 국가신약개발사업 선정"
By_BK Min, KDFN
kdf@kdfnews.com
Source_ⓒMedytox
